For a GBM setting, the threshold could be potentially exploited by a multi-gene, multi-drug approach able to target the three main genetic pathways of the AC-like, OPC-like and NPC-like populations through EGFR, PDGFRA and CDK4, respectively (Neftel 2019). This evidence concerns the gene EGFR and glioblastoma.